Shopping Cart
- Remove All
- Your shopping cart is currently empty
Thailanstatin D, an analogue of Thailanstatin A, inhibits AR-V7 gene splicing by disrupting the interaction between U2AF65 and SAP155, hindering their binding to the polypyrimidine tract situated between the branch point and the 3' splice site. This compound displays potent tumor inhibitory properties in human castration-resistant prostate cancer (CRPC) xenografts, resulting in cellular apoptosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder |
Description | Thailanstatin D, an analogue of Thailanstatin A, inhibits AR-V7 gene splicing by disrupting the interaction between U2AF65 and SAP155, hindering their binding to the polypyrimidine tract situated between the branch point and the 3' splice site. This compound displays potent tumor inhibitory properties in human castration-resistant prostate cancer (CRPC) xenografts, resulting in cellular apoptosis. |
In vitro | Thailanstatin D (0-50 nM; 4 hours) significantly reduces AR-V7 and other AR splice variants (AR-Vs)[1] protein levels and dose-dependently suppresses mRNA levels of AR-V7 and AR-FL in VCaP, 22RV1, and LN95 cell lines, as observed in a Cell Viability Assay[1]. |
In vivo | Thailanstatin D, administered at a dosage of 300 μg/kg through ALZET osmotic pumps daily for four days, significantly inhibited tumor growth in an animal model of NOD-SCID mice bearing 22RV1 xenografts. |
Molecular Weight | 519.635 |
Formula | C28H41NO8 |
Cas No. | 1609105-89-6 |
Relative Density. | 1.19 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.